Abstract
Upon viral exposure, antibodies serve as a first line of defense and can act by preventing infection or reducing the viral burden. The ability of antibodies to confer protection against HIV has been demonstrated by several studies using the passive transfer of neutralizing antibodies in the non-human primate challenge model. Therefore, efforts have been made to induce a similarly protective humoral immune response by vaccination with antigens derived from HIV. Thus far, the results have been disappointing. Humoral immune responses elicited via vaccination display activities that are generally much less potent and broad as compared to those induced during natural infection. However, recently there have been increased efforts to systematically identify and compare the epitopes potentially critical to the generation of protective antibody responses in the hope that this will lead to improved strategies and superior immunogen design. As a critical part of this process, novel methods to monitor protective antibody responses will also need to be vigorously explored and improved, then validated in both preclinical and clinical settings.
Keywords: HIV, antibodies, neutralization, epitopes
Current HIV Research
Title: Broadening Our View of Protective Antibody Responses Against HIV
Volume: 5 Issue: 6
Author(s): Brian Burke and Susan W. Barnett
Affiliation:
Keywords: HIV, antibodies, neutralization, epitopes
Abstract: Upon viral exposure, antibodies serve as a first line of defense and can act by preventing infection or reducing the viral burden. The ability of antibodies to confer protection against HIV has been demonstrated by several studies using the passive transfer of neutralizing antibodies in the non-human primate challenge model. Therefore, efforts have been made to induce a similarly protective humoral immune response by vaccination with antigens derived from HIV. Thus far, the results have been disappointing. Humoral immune responses elicited via vaccination display activities that are generally much less potent and broad as compared to those induced during natural infection. However, recently there have been increased efforts to systematically identify and compare the epitopes potentially critical to the generation of protective antibody responses in the hope that this will lead to improved strategies and superior immunogen design. As a critical part of this process, novel methods to monitor protective antibody responses will also need to be vigorously explored and improved, then validated in both preclinical and clinical settings.
Export Options
About this article
Cite this article as:
Burke Brian and Barnett W. Susan, Broadening Our View of Protective Antibody Responses Against HIV, Current HIV Research 2007; 5 (6) . https://dx.doi.org/10.2174/157016207782418533
DOI https://dx.doi.org/10.2174/157016207782418533 |
Print ISSN 1570-162X |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4251 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Prevention and Treatment of Bone Metastases
Current Pharmaceutical Design Application of Baculovirus-Insect Cell Expression System for Human Therapy
Current Pharmaceutical Biotechnology Image Guided Biopsy of Musculoskeletal Lesions with Low Diagnostic Yield
Current Medical Imaging Personalized Nanoparticles for Cancer Therapy: A Call for Greater Precision
Anti-Cancer Agents in Medicinal Chemistry Interleukin-6: A Critical Cytokine in Cancer Multidrug Resistance
Current Pharmaceutical Design Cell Arrest and Apoptosis Induced by the Next Generation of Vanadium Based Drugs: Action Mechanism to Structure Relation and Future Perspectives
Anti-Cancer Agents in Medicinal Chemistry Protocatechuic Acid and Human Disease Prevention: Biological Activities and Molecular Mechanisms
Current Medicinal Chemistry Clinical Development of Inhibitors of the Insulin-like Growth Factor Receptor in Oncology
Current Drug Targets Urokinase-a Very Popular Cardiovascular Agent
Recent Patents on Cardiovascular Drug Discovery The Role of cMet in Non-Small Cell Lung Cancer Resistant to EGFRInhibitors: Did We Really Find the Target?
Current Drug Targets The Human Glioma-Associated Oncogene Homolog 1 (GLI1) Family of Transcription Factors in Gene Regulation and Diseases
Current Genomics Interplay between DNA Methyltransferase 1 and microRNAs During Tumorigenesis
Current Drug Targets Potential Interactions between miRNAs and Hypoxia: A New Layer in Cancer Hypoxia
Anti-Cancer Agents in Medicinal Chemistry Therapeutically Targeting MicroRNAs in Liver Cancer
Current Pharmaceutical Design Lipid Rafts, Endoplasmic Reticulum and Mitochondria in the Antitumor Action of the Alkylphospholipid Analog Edelfosine
Anti-Cancer Agents in Medicinal Chemistry Potentials of Hydrogels in Cancer Therapy
Current Cancer Therapy Reviews Recent Developments of Flavonoids with Various Activities
Current Topics in Medicinal Chemistry Inhibition of Cdc42-Interacting Protein 4 (CIP4) Impairs Osteosarcoma Tumor Progression
Current Cancer Drug Targets Retraction Notice to Role of Vitamin K2 in the Treatment of Postmenopausal Osteoporosis
Current Drug Safety Cancer Kinases and its Novel Inhibitors: Past, Present and Future Challenges
Current Drug Targets